Viewing Study NCT06888856


Ignite Creation Date: 2025-12-24 @ 11:34 PM
Ignite Modification Date: 2026-01-01 @ 11:58 PM
Study NCT ID: NCT06888856
Status: NOT_YET_RECRUITING
Last Update Posted: 2025-03-21
First Post: 2025-03-17
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Multiple Myeloma is a Hematologic Malignancy Characterized by the Accumulation of Malignant Plasma Cells in the Bone Marrow. Despite Advances in Treatment, Many Patients Experience Disease Relapse. Bispecific Antibodies Offer an Innovative Therapeutic Approach, But Approximately 30%-40% of Patients
Sponsor: Tel-Aviv Sourasky Medical Center
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Outcomes Module Eligibility Module